Carisma Therapeutics Inc CARM.OQ CARM.O is expected to show a rise in quarterly revenue when it reports results on November 7 (estimated) for the period ending September 30 2024
The Cambridge Massachusetts-based company is expected to report a 42.8% increase in revenue to $5.467 million from $3.83 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Carisma Therapeutics Inc is for a loss of 26 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Carisma Therapeutics Inc is 8.00, above its last closing price of $1.10.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -0.31 | -0.30 | -0.27 | Beat | 9.2 |
Mar. 31 2024 | -0.47 | -0.43 | -0.46 | Missed | -6.4 |
Jan. 1 0001 | -0.55 | -0.52 | Beat | 5.9 | |
Sep. 30 2023 | -0.56 | -0.57 | -0.53 | Beat | 7 |
Jun. 30 2023 | -0.60 | -0.60 | -0.49 | Beat | 17.9 |
Jan. 1 0001 | -0.89 | -0.89 | -1.93 | Missed | -116.9 |
Dec. 31 2022 | -2.20 | -2.20 | -0.80 | Beat | 63.6 |
Sep. 30 2022 | -1.60 | -1.60 | 2.00 | Beat | 225 |
This summary was machine generated November 6 at 14:17 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。